logo

Quick Facts

Share

AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi or durvalumab in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival benefit at three years for adults with extensive-stage small cell lung cancer or ES-SCLC...

Merck & Co., Inc. (MRK) said it presented the full results from the pivotal Phase 3 KEYNOTE-826 trial at the European Society for Medical Oncology Congress 2021. The trial investigated the company's anti-PD-1 therapy KEYTRUDA in combination with chemotherapy with or without bevacizumab for the first-line...

Merck & Co., Inc. (MRK) said that the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with the company's anti-PD-1 therapy Keytruda, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), the trial's primary endpoint,...

Exelixis Inc. (EXEL) said that it presented detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib or CABOMETYX in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer or CRPC at the 2021 European Society of Medical Oncology...

AstraZeneca Plc. (AZN, AZN.L) and Daiichi Sankyo's HER2-directed antibody drug conjugate, Enhertu, demonstrated robust and durable tumor response of 54.9% in previously treated patients with HER2-mutant or HER2m unresectable and/or metastatic non-squamous non-small cell lung cancer or NSCLC. Data...

The U.S. Food and Drug Administration approved Exelixis Inc.'s (EXEL) Cabometyx or cabozantinib for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth...

Astellas Pharma Inc. and Pfizer Inc.'s (PFE) Xtandi or enzalutamide improved overall survival in men with metastatic hormone-sensitive prostate cancer, as per a phase 3 ARCHES Study. The Phase 3, randomized, double-blind, placebo-controlled trial compared Xtandi plus androgen deprivation therapy versus...

TTEC Holdings Inc. (TTEC) said that it resolved the cyber attack on its technology systems. TTEC noted that it became aware of the cyber incident on Sunday, September 12 and immediately started remediation and recovery efforts. The company isolated the systems involved and took other remedial measures...

Biogen Inc. (BIIB) announced the Committee for Medicinal Products for Human Use has recommended granting marketing authorization for VUMERITY in the European Union. VUMERITY is a next-generation oral fumarate for the treatment of adults with relapsing-remitting multiple sclerosis. The company said...

Corcept Therapeutics Inc. (CORT) said that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer were featured in a proffered paper oral presentation at the European Society for Medical Oncology...

United Airlines (UAL) said it will begin new service between Washington, D.C. and Lagos, Nigeria on November 29. The company noted that this flight is the only service between the U.S. and Nigeria to offer premium economy product. The airline will operate three weekly flights, and tickets will be...

Chico's FAS, Inc. (CHS) announced the appointment of Patrick Guido as Chief Financial Officer, effective September 20, 2021. Patrick Guido most recently served as Senior Vice President and Chief Financial Officer at Asbury Automotive Group, Inc. Prior to this role, Guido served as Executive Vice President...

Merck & Co., Inc. (MRK) said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative...

MasterCraft Boat Holdings, Inc. (MCFT) said the company is revising first quarter guidance due principally to a temporary delay in the shipment of a key component from a single engine parts supplier for the MasterCraft brand. The company reaffirmed its guidance for fiscal 2022. "By working closely...

Jackson Financial Inc. (JXN) reported an improved second-quarter adjusted operating earnings due largely to strong private equity investment returns and separate account growth. Jackson separated from Prudential plc on September 13, 2021, and the results mark the company's first quarterly earnings report...

Follow RTT